Shares of Eurofins Scient (OTCMKTS:ERFSF – Get Free Report) have been assigned an average recommendation of “Hold” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and one has given a strong buy recommendation to the company.
A number of equities research analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Eurofins Scient in a research note on Wednesday, October 29th. Citigroup reiterated a “neutral” rating on shares of Eurofins Scient in a report on Wednesday, October 22nd.
Read Our Latest Stock Analysis on ERFSF
Eurofins Scient Stock Performance
About Eurofins Scient
Eurofins Scientific is a global provider of bioanalytical testing and laboratory services, offering a wide array of testing solutions to pharmaceutical, food, environmental, agriscience and consumer products industries. Its core services include pharmaceutical quality control, environmental testing for water and air quality, food safety analysis, agrochemical trials and clinical diagnostic support. The company operates specialized laboratories equipped with advanced analytical technologies such as chromatography, mass spectrometry and molecular biology to ensure compliance with regulatory standards and to support research and development efforts across multiple sectors.
Founded in 1987 by Gilles Martin and headquartered in Luxembourg, Eurofins has grown through a combination of organic expansion and strategic acquisitions.
See Also
- Five stocks we like better than Eurofins Scient
- A month before the crash
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- The Last Gold Bull Market
Receive News & Ratings for Eurofins Scient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eurofins Scient and related companies with MarketBeat.com's FREE daily email newsletter.
